Remus Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Remus Pharmaceuticals Limited's yearly results (2022–2026), compared with companies in India. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 87% of companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹31Over the last 3 years, every ₹100 of reported profit came with ₹31 of operating cash.
Lower than 74% of companies in India.
Self-Funding Ratio
1.2×Over the last 3 years its own operating cash covered its investment spending (capex) 1.2 times.
Higher than 52% of companies in India.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 87% of companies in India.
Growth Efficiency Ratio
₹4Sales grew 3,293% in 3 years; of every extra ₹100 of sales, ₹4 became extra profit.
Lower than 68% of companies in India.
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
1.0×Debt due within a year is covered 1.0 times by its yearly operating cash.
Higher than 58% of companies in India.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Higher than 75% of companies in India.
Tangible Assets Ratio
98%Of every ₹100 the company owns, ₹98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 66% of companies in India.
Tangible Net Worth Ratio
97%Of every ₹100 of net worth, ₹97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 63% of companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Remus Pharmaceuticals Limited owes ₹0.33 for every ₹1 it owns. Net profit rose 27% in the year to Mar 2026.
Compared with companies in India · latest annual results Mar 2026.
P/E ratio
48.8Investors pay ₹48.8 for every ₹1 of Remus Pharmaceuticals Limited's yearly profit, higher than 80% of companies in India.
P/B ratio
3.03The share price is 3.03 times Remus Pharmaceuticals Limited's book value per share, higher than 59% of companies in India.
Market cap
₹1,062 CrThe total market value of all of Remus Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 59% of companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹351 CrWhat Remus Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹297.85Net worth divided by the number of shares. The share price of ₹901.20 is 3.0 times this, which is the P/B above.
Owes vs Owns
0.33×Remus Pharmaceuticals Limited owes ₹0.33 for every ₹1 it owns (low), lower than 65% of companies in India.
Revenue growth
+37%Revenue rose 37% in the year to Mar 2026.
Profit growth
+27%Net profit rose 27% in the year to Mar 2026.
Profit margin
4.4%Remus Pharmaceuticals Limited keeps ₹4 of every ₹100 of revenue as net profit.
Cash quality
0.5×Cash from Remus Pharmaceuticals Limited's business was 0.5× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
36.7×Remus Pharmaceuticals Limited's operating profit covered its interest costs 36.7 times in the year to Mar 2026.
Cash vs debt
Net cashRemus Pharmaceuticals Limited held ₹28 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Remus Pharmaceuticals Limited's P/E ratio?
Investors pay ₹48.8 for every ₹1 of Remus Pharmaceuticals Limited's yearly profit, higher than 80% of companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Remus Pharmaceuticals Limited: ₹1,062 Cr ÷ ₹351 Cr (31 Mar 2026) = 3.0.
How much does Remus Pharmaceuticals Limited owe compared with what it owns?
Remus Pharmaceuticals Limited owes ₹0.33 for every ₹1 it owns (low), lower than 65% of companies in India.
Is Remus Pharmaceuticals Limited's revenue growing?
Revenue rose 37% in the year to Mar 2026.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.